Aptose Biosciences Inc. Files 8-K
Ticker: APTOF · Form: 8-K · Filed: Feb 12, 2025 · CIK: 882361
Sentiment: neutral
Topics: disclosure, financials, corporate-history
Related Tickers: APTO
TL;DR
APTO filed an 8-K on Feb 12, 2025, covering Reg FD and financials. Stay updated.
AI Summary
Aptose Biosciences Inc. filed an 8-K on February 12, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Lorus Therapeutics Inc. and Imutec Pharma Inc., is incorporated in Canada and operates in the Biological Products sector.
Why It Matters
This filing provides an update on Aptose Biosciences Inc.'s regulatory and financial disclosures, which is important for investors to stay informed about the company's compliance and financial status.
Risk Assessment
Risk Level: low — This is a routine filing of an 8-K, which typically contains disclosures and exhibits rather than significant new events.
Key Players & Entities
- Aptose Biosciences Inc. (company) — Registrant
- Lorus Therapeutics Inc. (company) — Former company name
- Imutec Pharma Inc (company) — Former company name
- February 12, 2025 (date) — Date of earliest event reported
FAQ
What is the primary purpose of this 8-K filing?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact name of the registrant as specified in its charter?
The exact name of the registrant is Aptose Biosciences Inc.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on February 12, 2025.
What are some of the former names of Aptose Biosciences Inc.?
Some of the former names of Aptose Biosciences Inc. include Lorus Therapeutics Inc. and Imutec Pharma Inc.
In which state or other jurisdiction was Aptose Biosciences Inc. incorporated?
Aptose Biosciences Inc. was incorporated in Canada.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 9.7 · Accepted 2025-02-12 07:30:11
Filing Documents
- f8k_021225.htm (8-K) — 15KB
- exh_991.htm (EX-99.1) — 10KB
- 0001171843-25-000754.txt ( ) — 225KB
- gnw-20190101.xsd (EX-101.SCH) — 3KB
- gnw-20190101_def.xml (EX-101.DEF) — 25KB
- gnw-20190101_lab.xml (EX-101.LAB) — 33KB
- gnw-20190101_pre.xml (EX-101.PRE) — 22KB
- f8k_021225_htm.xml (XML) — 3KB
01. Regulation FD Disclosure
Item 7.01. Regulation FD Disclosure. On February 12, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference. In accordance with General Instruction B.2 of Form 8-K, the information in the press release attached as Exhibit 99.1 hereto shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 Press Release dated February 12, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Aptose Biosciences Inc. Date: February 12, 2025 By: /s/ William G. Rice, Ph.D. William G. Rice, Ph.D. President and Chief Executive Officer